Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) Stock Overview
Explore Spyre Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
4.5B
P/E Ratio
-142.81
EPS (TTM)
$-2.12
ROE
-0.31%
SYRE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Spyre Therapeutics, Inc. (SYRE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 57.81, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $32.96.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -142.81 and a market capitalization of 4.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.